INGELHEIM, Germany -- (BUSINESS WIRE) --
Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’.
Equine lameness is truly common and impacts horse performance as well as equine welfare1. Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.
Arti-Cell® Forte is a groundbreaking first-ever approved therapy, developed towards targeting lameness, utilising specifically primed, chondrogenic induced stem cells. Arti-Cell® Forte comes in an ultra-low frozen ready-to-use presentation.
Boehringer Ingelheim and Global Stem cell Technology (GST), that formed a partnership last year, have the same ambition to bring new treatments and solutions to improve animal health; therefore, Arti-Cell® Forte was specifically designed for horses to provide a convenient and long-term2 solution for recurrent lameness.
“A quarter of the entire equine population1 develops osteoarthritis at some point in their life. Priming the cells towards cartilage aids them to deliver the right activities in the affected joint,” says Jan Spaas, CEO of GST. “We are absolutely delighted with our first marketing authorisation from the European Commission and the first stem cell-based product in Animal Health. We are sure that with our partner Boehringer Ingelheim this product will become a game changer in equine health.”
Dr. Erich Schoett, Head of the Global Strategic Business Unit Equine at Boehringer Ingelheim, shares: “We are proud to continue to set new standards of care for horses to optimise their health and well-being in partnership with veterinarians. Early disease detection and early treatment are key to ensure that horses are healthy and live longer, happier lives. Arti-Cell® Forte as the first-ever approved stem cell-based product offers to veterinarians and horse owners a ready-to-use solution to help raising the health and quality of life for horses with mild to moderate recurrent lameness”.
Following the scientific review by the European Medicines Agency2 and decision of EU marketing authorisation by the European Commission, Arti-Cell® Forte is now approved as a veterinary medicine for the treatment of equine lameness. It will be available from May and June 2019 onwards in a range of European Countries.
Intended audiences
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Enviva森林保护基金公布2022年资助对象
游历于艺术界的资深书法家陆林深-曾探访美、
2020中国全过程工程咨询行业综合实力百强榜单
“第三届中国最美露营地颁奖盛典” 在京隆重
文旅融合绘就“诗与远方”
全国政协:束昱辉政协全国委员会委员资格被撤
上饶:弘扬爱卫新风尚 培养健康新生活
广饶公安千里追踪破获侵犯公民个人信息案!
滨州市滨城区玉龙湖小学2015级1班家长进进课堂
上饶:早稻机收减损促增产 颗粒归仓保丰收
Notice of ABB’s Annual Meeting
皇尊庄园2021年度安全工作会议召开
GSMA:全球所有领先的物联网运营商即日起将提
银河娱乐集团2020年第二季度及中期业绩
国际护士节:礼赞无私大爱 致敬白衣天使
LambdaTest为其端到端测试编排平台Hyper
iEnglish英语风采秀助力11岁男孩的“外交官之梦
Elliptic Labs与传音智能手机联手
青岛活动搭建、冰激凌机租赁、亲子活动道具信
健康宅家,知识战疫,咪咕中信书店价值万元精
83天!200亿件!快递业务量增长再提速
Blue Yonder助力零售商打造个性化全渠道商务体验
迪拜水电局开放2022年水资源、能源、环保科技
Rambus推出6400MT/s DDR5寄存时钟驱动器